Latest Content

Combining genetic features with clinical data improved the performance of a pulmonary fibrosis prediction score for people with rheumatoid arthritis.

Pigment epithelial detachment and hyperreflective foci had better early control in age-related macular degeneration (AMD) when treated with faricimab.

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

Telehealth has quickly become a central part of the mental health system among younger, higher-income, college-educated, and privately insured patients.

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and offering convenient self-injection treatment.

Ryan Haumschild, PharmD, MS, MBA, discusses key considerations for pharmacists to ensure access to cutting-edge therapies for patients with cancer.

The latest advancements in idiopathic pulmonary fibrosis (IPF) treatment offer promising efficacy and improved tolerability.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

The expansion of direct-to-consumer (DTC) pharmaceutical manufacturer models and the upcoming TrumpRx launch offer lower costs but create new complexities for patients.